Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) P. aeruginosa Isolates from a Global Surveillance Program

ConclusionsC-T had potent activity against P. aeruginosa isolated from patients in hospitals in 4 continents. C-T was more active than all comparators, except COL, and maintained activity against MDR and XDR isolates and isolates non-susceptible to all 4 tested BLs. C-T was active against 12/16 COL-NS isolates.
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research

Related Links:

Condition:   Urinary Tract Infections Interventions:   Drug: Concentrated herbal extract granules TRA;   Drug: Placebo Sponsors:   Changhua Christian Hospital;   Ministry of Health and Welfare, Taiwan Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractLung ultrasound (US) cannot be considered a new diagnostic imaging technique anymore, with some articles dating back 50  years. The question that hovers over it recently is why it is still not widely accepted, like chest radiography. So, have we wasted a lot of time without using lung US, or are we wasting our time using lung US? The main goals of this article are to underline all the advantages, potentials and reas ons to use lung US in everyday clinical practice, but also to address the main concerns linked to this imaging tool. From the standpoint of an experienced pediatric radiologist from a tertiary heal...
Source: Pediatric Radiology - Category: Radiology Source Type: research
Publication date: Available online 16 February 2020Source: Microbial PathogenesisAuthor(s): Bo Li, Xiaoqian Lan, Li Wang, Jiani Zhao, Jingli Ding, Hao Ding, Jun Lei, Yiping Wei, Wenxiong ZhangAbstractBackgroundHelicobacter pylori (H. pylori) infection is one of the important risk factors of gastric related diseases and antibiotic therapy has become an effective treatment. At present, proton-pump inhibitor and amoxicillin-based triple therapy, including clarithromycin (PAC) and metronidazole (PAM), are two commonly used first-line therapies for H. pylori infection, which has a high incidence and possibly poor prognosis worl...
Source: Microbial Pathogenesis - Category: Infectious Diseases Source Type: research
Publication date: Available online 15 February 2020Source: Journal of Hazardous MaterialsAuthor(s): Fisseha A Bezza, Shepherd M Tichapondwa, Evans MN ChirwaAbstractUniformly dispersed silver nanoparticles (AgNPs) with remarkable colloidal stability were synthesized using chemical reduction method in lipopeptide biosurfactant reverse micelles. Transmission Electron microscopy (TEM), Scanning electron microscopy (SEM) and UV–vis spectroscopy analysis exhibited monodisperse nanoparticles with spherical morphology of diameter of 21 ± 2. The lipopeptide stabilized AgNPs displayed remarkable antibacter...
Source: Journal of Hazardous Materials - Category: Environmental Health Source Type: research
Source: Infection and Drug Resistance - Category: Infectious Diseases Tags: Infection and Drug Resistance Source Type: research
Walking pneumonia causes milder symptoms than pneumonia, including being tired and having a sore throat, fever, and cough, the CDC says. Symptoms can be mild, more like a bad cold, but it can still lead to pneumonia.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
An eight-member expert committee constituted by the government to assess availability of medicines in the country has suggested imposing export restrictions on 12 drugs including antibiotics like chloramphenicol, neomycin, metronidazole, azythromicin, clindamycin; vitamin B1, B2 and B6; as well as hormones like progesterone used during pregnancy and in menstrual related problems.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
ConclusionsThe CAUTI incidence is reduced through QCC, providing a useful reference for the prevention of CAUTI and the development of medical quality improvement activities.
Source: American Journal of Infection Control - Category: Infectious Diseases Source Type: research
AbstractImipenem ‐cilastatin‐relebactam (IMI‐REL) is a novel β‐lactam–β‐lactamase inhibitor combination recently approved for the treatment of complicated urinary tract infections (cUTIs) and complicated intraabdominal infections (cIAIs). Relebactam is a β‐lactamase inhibitor with the ability to inh ibit a broad spectrum of β‐lactamases such as class A and class C β‐lactamases, including carbapenemases. The addition of relebactam to imipenem restores imipenem activity against several imipenem‐resistant bacteria, including Enterobacteriaceae andPseudomonas aeruginosa. Clinica...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Tags: REVIEW OF THERAPEUTICS Source Type: research
Authors: Graul AI, Pina P, Tracy M, Sorbera L Abstract Highlights of our annual review of new approvals and launches on global drug markets include the approval and launch of Trikafta, the most widely applicable treatment to date for cystic fibrosis; approval of the first Ebola vaccine for general (rather than emergency) use; the pilot rollout in three African countries of the world's first malaria vaccine; approval of a new treatment option for multidrug-resistant bacterial infections; and the approval and launch in China of the first new drug to treat Alzheimer's disease in more than a decade. Several new immune ...
Source: Drugs of Today - Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research
More News: Antimicrobial Resistance | Infectious Diseases | Levaquin | Metronidazole | Multidrug Resistance | Pneumonia | Pyelonephritis | Skin | Study | Urinary Tract Infections